Trial · NCT03452943
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the TTS of the YGTSS at Week 12 | TEV-50717 | -9.1 | Standard Error 1.28 | units on a scale | |
| Change From Baseline in the TTS of the YGTSS at Week 12 | Placebo | -8.4 | Standard Error 1.25 | units on a scale | |
| Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 12 | TEV-50717 | -0.7 | Standard Error 0.13 | units on a scale | |
| Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 12 | Placebo | -0.7 | Standard Error 0.12 | units on a scale | |
| Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 12 | TEV-50717 | -0.7 | Standard Error 0.18 | units on a scale | |
| Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 12 | Placebo | -0.4 | Standard Error 0.14 | units on a scale | |
| Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 12 | TEV-50717 | -9.9 | Standard Error 2.37 | units on a scale | |
| Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 12 | Placebo | -8.8 | Standard Error 2.27 | units on a scale | |
| Percentage of Participants With Adverse Events | TEV-50717 | Any AEs | 65.5 | percentage of participants | |
| Percentage of Participants With Adverse Events | Placebo | Any AEs | 55.9 | percentage of participants | |
| Percentage of Participants With Adverse Events | TEV-50717 | Treatment-related AEs | 50.0 | percentage of participants | |
| Percentage of Participants With Adverse Events | Placebo | Treatment-related AEs | 20.3 | percentage of participants | |
| Percentage of Participants With Adverse Events | TEV-50717 | Serious AEs | 0 | percentage of participants | |
| Percentage of Participants With Adverse Events | Placebo | Serious AEs | 0 | percentage of participants | |
| Percentage of Participants With Adverse Events | TEV-50717 | AEs leading to discontinuation | 1.7 | percentage of participants | |
| Percentage of Participants With Adverse Events | Placebo | AEs leading to discontinuation | 1.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03452943/results